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Background. The efﬁcacy of antiretrovirals as postexposure prophylaxis (PEP) to prevent viral acquisition was dem-
onstrated in nonhuman primate models of human immunodeﬁciency virus (HIV) in the early 1990s. To complement
the evidence base for efﬁcacy of HIV PEP in humans, we systematically reviewed the published data on PEP efﬁcacy
across animal studies.
Methods. PubMed, Web of Science, and Embase were searched from inception to 31 May 2014 for randomized
and nonrandomized studies reporting seroconversions among uninfected animals exposed to HIV or simian immu-
nodeﬁciency virus, irrespective of route of exposure. Seroconversion risk data were pooled using random-effects
models, and associations explored through meta-regression.
Results. Twenty-ﬁve studies (408 primates) were included for review. The risk of serconversion was 89% lower
among animals exposed to PEP compared with those that did not receive PEP (odds ratio, 0.11 [95% conﬁdence
interval, .05–.23]). Heterogeneity was low (I2 = 0.0%). In meta-regression, a signiﬁcant association was found be-
tween timing of PEP and seroconversion and the use of tenofovir compared with other drugs.
Conclusions. This review provides further evidence of the protective beneﬁt of PEP in preventing HIV acquisi-
tion, and the importance of initiating PEP as early as possible following virus exposure.
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The efﬁcacy of antiretroviral drugs as postexposure pro-
phylaxis (PEP) to prevent viral infection was ﬁrst dem-
onstrated in nonhuman primate models in the early
1990s [1, 2], and subsequently shown in humans by a
case-control study in 1997 [3]. Because of the ethical
difﬁculties involved in carrying out further studies in
humans, subsequent controlled studies of PEP efﬁcacy
have been conducted in primate models, especially
simian immunodeﬁciency virus (SIV) infection of
macaques [4].
A systematic review of PEP for human occupational
human immunodeﬁciency virus (HIV) exposure
concluded that a formal systematic review of all relevant
animal studies was warranted because the rationale
for PEP is partly based on results from individual pri-
mary animal studies [5]. To complement the evidence
base for HIV PEP, we systematically reviewed the pub-
lished data on PEP efﬁcacy across nonhuman primate
studies.
METHODS
This systematic review was conducted according to a
study protocol following the requirements of the PRIS-
MA (Preferred Reporting Items for Systematic Reviews
and Meta-Analyses) statement [6].
Search Strategy and Selection Process
We searched online databases (PubMed, Web of Sci-
ence, and Embase) from inception to 31 May 2014,
using a highly sensitive search strategy for each database
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following a predeﬁned study protocol. Randomized and non-
randomized studies were included if they reported seroconver-
sions among uninfected animals exposed to HIV or SIV
irrespective of route of exposure and at least 1 animal was sub-
sequently given 1 or more antiretroviral drugs as PEP. Only
nonhuman primate studies were included in the ﬁnal review.
Human studies, in vitro studies, and studies where outcomes
were not reported were excluded. No date, geographic, or lan-
guage restrictions were applied.
Data were extracted independently and in duplicate by 2 au-
thors (C. I., Z. S.) using a standardized data extraction form on
key study variables including the following outcome variables:
number of animals exposed to virus, type, timing and duration
of intervention, and number seroconverting. Study quality was
assessed using an adapted version of the Collaborative Approach
to Meta-Analysis and Review of Animal Data from Experimental
Studies quality checklist, as follows: (1) publication in a peer-
reviewed journal, (2) allocation concealment, (3) randomization
to treatment or control group, (4) blinded assessment of out-
come, (5) sample size calculation, (6) statement of compliance
with regulatory requirements, and (7) statement regarding possi-
ble conﬂicts of interest [7].
Data Analysis
To assess the efﬁcacy of the antiretrovirals in preventing virus ac-
quisition, odds ratios (ORs) and corresponding 95% conﬁdence
intervals (CIs) were calculated for each study comparing serocon-
version among animals in the intervention group (receiving anti-
retrovirals) with those who are in the control group (receiving
placebo, or untreated controls). In the case of zero outcome events
in one arm, the Haldane method was applied, adding 0.5 to each
arm [8]. Estimates were pooled using a DerSimonian–Laird
random-effects model [9]. Cumulative meta-analysis was used
in which the pooled estimates of each study is pooled each time
the results of a new study are published to display the accumula-
tion of evidence over time [10]. Heterogeneity was assessed using
the I2 statistic [11]. The potential difference of running a ﬁxed-
effects model was explored in sensitivity analysis. Sources of po-
tential study heterogeneity were explored through a preplanned
subgroup analysis to assess the inﬂuence of number of drugs
and duration of PEP on odds of seroconversion. The inﬂuence
of timing of PEP initiation and type of drug was evaluated
through meta-regression. For those animals receiving the inter-
vention, the proportion seroconverting was estimated together
with corresponding 95% CIs, and data were transformed to sta-
bilize the variance in the raw proportions prior to meta-regres-
sion [12, 13]. Publication bias was assessed for the primary
outcome of treatment discontinuation by funnel plot and the
Egger’s test for small study effects [14]. All analyses were con-
ducted using Stata software, version 12 (StataCorp, College Sta-
tion, Texas), with a P value <.05 considered to be statistically
signiﬁcant.
RESULTS
From a total of 2517 titles screened, 25 studies were taken through
for full review, providing data on 408 primates exposed to HIV or
SIV (Figure 1) [1, 15–37]. Studies were conducted across 5 coun-
tries (United States, France, Japan, Sweden, and China), between
1990 and 2014 (average, 2002). The main species used were rhesus
macaques (10 studies) or cynomolgus monkeys (5 studies). The
main route of virus exposure was intravenous exposure (17 stud-
ies). The main route of drug administration was subcutaneous ad-
ministration (10 studies). Three studies were randomized [24, 33,
Figure 1. Study selection process. Abbreviations: ART, antiretroviral therapy; ARV, antiretroviral; PEP, postexposure prophylaxis; PMTCT, prevention of
mother-to-child transmission; PrEP, preexposure prophylaxis.
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34], but none reported allocation concealment, blinded assessment
of outcomes, or sample size calculations.
Sixteen studies provided evaluable data for the assessment
of PEP efﬁcacy comparing PEP (180 primates) against controls
(103 primates). The risk of serconversion was 89% lower
among animals exposed to PEP compared with those that
did not receive PEP (OR, 0.11 [95% CI, .05–.23]). Heterogene-
ity was low (I2 = 0.0%). Individual study estimates and pooled
results are shown in Figure 2. This result did not differ if a
ﬁxed-effects model was used (OR, 0.10 [95% CI, .05–.20];
I2 = 0.0%). We did not identify evidence of publication bias
(P = .12).
In subgroup analysis, there was no difference in the odds of
seroconversion by number of drugs (P > .05); however, this
comparison is limited by the fact that the majority of studies
(n = 13) administered a single antiretroviral agent as part
of PEP. In univariate meta-regression, a signiﬁcant associa-
tion was found between timing of PEP and seroconversion (β
coefﬁcient < 0.01 [95% CI, <.01–.01]; P = .03) Lower sero-
conversion was also associated with the use of tenofovir com-
pared with other drugs (β coefﬁcient −0.23 [95% CI, −.42 to
–.38]; P = .02).
DISCUSSION
This work provides the ﬁrst systematic review and meta-analysis
of PEP studies in nonhuman primate models of HIV. We were
able to pool data across 18 studies, increasing the conﬁdence in
the estimate of the effect of PEP in preventing SIV or HIV ac-
quisition, and found evidence supporting the importance of ini-
tiating PEP as early as possible following virus exposure. These
ﬁndings also demonstrate the growing trend in efﬁcacy as over
time studies began to use more potent drugs (eg, tenofovir in-
stead of zidovudine) with more favorable pharmacokinetics,
and lower doses of SIV infection that more closely resemble nat-
ural HIV infection.
Strengths of this review include a broad search strategy that
evaluated >2000 titles, and compliance with standard approach-
es to limit potential errors and biases that can be introduced in
the conduct of systematic reviews. Although we have made
every attempt to systematically and robustly explore these
data, there are a number of limitations that should be consid-
ered. The overall quality of the included studies was relatively
low and no study performed a sample size calculation, and as
such, our review may include studies that are underpowered.
Figure 2. Cumulative meta-analysis of the pooled odds of seroconversion. Abbreviations: 3TC, lamivudine; AZT, azidothymidine; BEA-005, 2′,3′-dideoxy-
3′-hydroxymethyl cytidine; CG, carregeenan gel; CI, conﬁdence interval; d4T, stavudine; FTC, emtricitabine; IDV, indinavir; RAL, raltegravir; TDF, tenofovir
disoproxyl fumarate; TFV, tenofovir; ZA, zinc acetate.
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In addition, previous animal review work has suggested that an
absence of blinding or randomization can have an impact on
observed outcomes [38]. The inconsistency in reporting of
data across studies limited our ability to assess other outcomes
that could potentially inform clinical practice, notably duration
of treatment and number or class of antiretroviral. Although we
would have liked to perform a sensitivity analysis for the impact
of study quality, it was not possible in the described dataset.
Finally, only studies in the public domain are included in this
review and although our analyses did not suggest publication
bias it is still feasible that reporting and publication bias exist
within this literature.
The estimated protective beneﬁt of PEP in this meta-analysis
(OR, 0.11 [95% CI, .05–.23]) was greater and more precise than
that reported in the case-control study in humans (OR, 0.19
[95% CI, .06–.52]) [3]. These differences may partly be the result
of the larger sample size in our study, and may suggest a greater
protective efﬁcacy than previously reported, although any infer-
ences derived from animal studies should be interpreted with cau-
tion. This emphasis on timing of PEP is in line with the early
biological mechanisms of infection illustrating a narrow window
of opportunity descriptive of the early stages of viral replication
that occur locally before the virus disseminates systemically [39].
Animal models can help to obtain critical pathophysiological
information that cannot always be gleaned from human studies.
The strengths of the primate model in the case of HIV PEP in-
clude (1) the window it provides on critical events that precede
the earliest time clinical signs and symptoms of HIV type 1
(HIV-1) infection disease are manifest; (2) ability to control
the virus strain and inoculum dose to achieve infection of a
high proportion of animals within a known number of exposures;
(3) access to relevant tissues in a relevant time frame, which in-
creases chances to directly observe virus–host cell interactions
and critical events; and (4) similarities in anatomy, physiology,
and immunology of the rhesus macaques to humans, and the ge-
neral similarities of pathogenic SIV infection to HIV-1 infection
in CD4 T-cell depletion, pathology, and AIDS [40].
Beyond informing proof-of-concept of an intervention strat-
egy that can be translated into clinical practice, the purpose of
animal model studies can be to prove a hypothesis in a biolog-
ical system, or to provide a platform for future research. Despite
the many similarities of animals models, inherent differences in
route of inoculation, virus titer, drug dose, and duration of in-
tervention, as well as innate biological differences, all caution
against absolute inferences from animal to human studies. Pre-
vious studies [41] have suggested that approximately one-third
of highly cited animal research translates at the level of human
clinical trials, but in some speciﬁc animal model ﬁelds there
have been suggestions that there is too much noise in the animal
data to extrapolate ﬁndings directly to clinical trials [42]. Data
from animal models—despite their limitations—can guide
human clinical trials; however, the results of such trials must
also feed back continuously into the animal model, so that
the animal models can be further improved to increase their rel-
evance and predictability for subsequent clinical trials.
In conclusion, the ﬁndings of this review provide further ev-
idence supporting the use of PEP to reduce the risk of HIV in-
fection following exposure to HIV.
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